Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jakavi

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

Bayer symbol

Bayer to research cancer immunotherapies with Compugen

Will develop drugs that boost response of body’s immune system to tumours

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Novartis building

Novartis lifts 2013 guidance on delay to Diovan generics

Reveals scale of payments to former CEO Daniel Vasella

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

Novartis sponsors rare disease patient community

Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links